HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of total hyphema with relatively low-dose tissue plasminogen activator.

Abstract
The purpose of this study is to investigate the efficacy of tissue plasminogen activator (tPA) in the treatment of total hyphema following ocular trauma or intraocular surgery. Three patients (3 eyes) representing unresolved total hyphema for more than 5 days and uncontrolled high intraocular pressure received intracameral injections of 10 microgram of recombinant tPA. Intracameral tPA injection resulted in complete resolution of hyphema in all 3 eyes. Resolution occurred mostly within 24 to 48 hours after injection. Possible side effects of tPA injection, such as increased intraocular pressure and corneal edema, were not observed. However, 1 eye had vitreous hemorrhage after repeated injections of tPA. Intracameral injection of tPA seems to be a safe and effective method for the treatment of unresolved total hyphema. However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.
AuthorsM H Kim, T H Koo, W J Sah, S M Chung
JournalOphthalmic surgery and lasers (Ophthalmic Surg Lasers) Vol. 29 Issue 9 Pg. 762-6 (Sep 1998) ISSN: 1082-3069 [Print] United States
PMID9760614 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator
Topics
  • Adult
  • Aged
  • Anterior Chamber (diagnostic imaging, pathology)
  • Cataract Extraction (adverse effects)
  • Child
  • Diabetes Complications
  • Eye Injuries (complications, diagnosis, surgery)
  • Female
  • Fibrinolytic Agents (administration & dosage, therapeutic use)
  • Follow-Up Studies
  • Humans
  • Hyphema (diagnosis, drug therapy, etiology)
  • Injections
  • Male
  • Postoperative Complications (diagnosis, drug therapy, etiology)
  • Recombinant Proteins
  • Tissue Plasminogen Activator (administration & dosage, therapeutic use)
  • Ultrasonography
  • Visual Acuity
  • Vitrectomy (adverse effects)
  • Wounds, Nonpenetrating (complications, diagnosis, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: